See more : PARK24 Co., Ltd. (PKCOF) Income Statement Analysis – Financial Results
Complete financial analysis of Eli Lilly and Company (LLY.DE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eli Lilly and Company, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- PT Cerestar Indonesia Tbk (TRGU.JK) Income Statement Analysis – Financial Results
- Winsome Breweries Limited (WINSOMBR.BO) Income Statement Analysis – Financial Results
- Nine Dragons Paper (Holdings) Limited (NDGPF) Income Statement Analysis – Financial Results
- iWallet Corporation (IWAL) Income Statement Analysis – Financial Results
- Cardax, Inc. (CDXI) Income Statement Analysis – Financial Results
Eli Lilly and Company (LLY.DE)
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 34.12B | 28.54B | 28.32B | 24.54B | 22.32B | 21.49B | 22.87B | 21.22B | 19.96B | 19.62B | 23.11B | 22.60B | 24.29B | 23.08B | 21.84B | 20.38B | 18.63B | 15.69B | 14.65B | 13.86B | 12.58B | 11.08B | 11.54B | 10.86B | 10.00B | 9.24B | 8.52B | 7.35B | 6.76B | 5.71B | 6.45B | 6.17B | 5.73B | 5.19B | 4.18B | 4.07B | 3.64B | 3.72B | 3.27B |
| Cost of Revenue | 7.08B | 6.63B | 7.31B | 5.48B | 4.72B | 4.68B | 6.07B | 5.65B | 5.04B | 4.93B | 4.91B | 4.80B | 5.07B | 4.37B | 4.25B | 4.38B | 4.25B | 3.55B | 3.47B | 3.22B | 2.68B | 2.18B | 2.16B | 2.06B | 1.66B | 1.52B | 1.85B | 1.57B | 1.33B | 1.25B | 1.56B | 1.53B | 1.35B | 1.28B | 1.03B | 1.13B | 1.12B | 1.17B | 1.04B |
| Gross Profit | 27.04B | 21.91B | 21.01B | 19.06B | 17.60B | 16.81B | 16.80B | 15.57B | 14.92B | 14.68B | 18.21B | 17.81B | 19.22B | 18.71B | 17.59B | 16.00B | 14.38B | 12.14B | 11.17B | 10.63B | 9.91B | 8.90B | 9.38B | 8.81B | 8.34B | 7.71B | 6.66B | 5.77B | 5.43B | 4.46B | 4.89B | 4.64B | 4.37B | 3.92B | 3.15B | 2.94B | 2.53B | 2.55B | 2.23B |
| Gross Profit Ratio | 79.25% | 76.77% | 74.18% | 77.66% | 78.85% | 78.22% | 73.46% | 73.35% | 74.76% | 74.85% | 78.76% | 78.78% | 79.13% | 81.08% | 80.55% | 78.49% | 77.20% | 77.40% | 76.28% | 76.74% | 78.74% | 80.35% | 81.28% | 81.07% | 83.42% | 83.49% | 78.24% | 78.56% | 80.31% | 78.16% | 75.81% | 75.21% | 76.34% | 75.43% | 75.42% | 72.17% | 69.30% | 68.59% | 68.23% |
| Research & Development | 13.11B | 7.19B | 7.03B | 6.09B | 5.60B | 5.05B | 5.28B | 5.24B | 4.80B | 4.73B | 5.53B | 5.28B | 5.02B | 4.88B | 4.33B | 3.84B | 3.49B | 3.13B | 3.03B | 2.69B | 2.35B | 2.15B | 2.24B | 2.02B | 1.78B | 1.74B | 1.38B | 1.19B | 1.04B | 838.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.82B | 6.44B | 6.43B | 6.12B | 6.21B | 5.98B | 6.59B | 6.45B | 6.53B | 6.62B | 7.13B | 7.51B | 7.88B | 7.05B | 6.89B | 6.63B | 6.10B | 4.89B | 4.50B | 4.28B | 4.06B | 3.42B | 3.42B | 3.23B | 2.76B | 2.66B | 2.31B | 1.99B | 1.85B | 1.40B | 3.84B | 3.11B | 2.30B | 2.13B | 1.76B | 1.69B | 1.75B | 1.51B | 1.33B |
| Selling & Marketing | 1.12B | 1.00B | 1.20B | 1.10B | 6.21B | 5.98B | 6.59B | 6.45B | 6.53B | 6.62B | 7.13B | 7.51B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.94B | 6.44B | 6.43B | 6.12B | 6.21B | 5.98B | 6.59B | 6.45B | 6.53B | 6.62B | 7.13B | 7.51B | 7.88B | 7.05B | 6.89B | 6.63B | 6.10B | 4.89B | 4.50B | 4.28B | 4.06B | 3.42B | 3.42B | 3.23B | 2.76B | 2.66B | 2.31B | 1.99B | 1.85B | 1.40B | 3.84B | 3.11B | 2.30B | 2.13B | 1.76B | 1.69B | 1.75B | 1.51B | 1.33B |
| Other Expenses | 0.00 | -52.10M | 112.80M | 1.50B | 611.80M | 145.60M | 110.10M | -8.30M | 174.80M | 368.30M | 63.90M | -41.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 439.70M | 490.40M | 509.80M | 543.50M | 553.70M | 432.20M | 398.30M | 368.10M | 299.50M | 247.50M | 229.30M | 204.00M | 184.30M | 177.70M | 136.20M |
| Operating Expenses | 20.05B | 13.63B | 13.46B | 12.21B | 11.81B | 11.03B | 11.87B | 11.70B | 11.33B | 11.35B | 12.66B | 12.79B | 12.90B | 11.94B | 11.22B | 10.47B | 9.58B | 8.02B | 7.52B | 6.98B | 6.41B | 5.57B | 5.65B | 5.25B | 4.98B | 4.89B | 4.21B | 3.72B | 3.45B | 2.67B | 4.24B | 3.48B | 2.60B | 2.38B | 1.98B | 1.89B | 1.93B | 1.69B | 1.47B |
| Cost & Expenses | 27.14B | 20.26B | 20.77B | 17.69B | 16.53B | 15.71B | 17.94B | 17.35B | 16.37B | 16.29B | 17.57B | 17.59B | 17.97B | 16.30B | 15.47B | 14.85B | 13.83B | 11.57B | 11.00B | 10.20B | 9.08B | 7.75B | 7.81B | 7.30B | 6.64B | 6.41B | 6.06B | 5.30B | 4.78B | 3.92B | 5.80B | 5.01B | 3.96B | 3.65B | 3.01B | 3.02B | 3.05B | 2.86B | 2.51B |
| Interest Income | 173.60M | 62.80M | 25.40M | 33.00M | 80.40M | 161.30M | 167.30M | 108.70M | 87.00M | 121.00M | 119.70M | 105.00M | 79.90M | 51.90M | 75.20M | 210.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 485.90M | 331.60M | 339.80M | 359.60M | 400.60M | 272.10M | 225.00M | 185.20M | 161.20M | 148.80M | 160.10M | 177.80M | 186.00M | 185.50M | 261.30M | 228.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.53B | 1.52B | 1.55B | 1.32B | 1.23B | 1.61B | 1.57B | 1.50B | 1.43B | 1.38B | 1.45B | 1.46B | 1.37B | 1.33B | 1.30B | 1.12B | 1.05B | 801.80M | 726.40M | 597.50M | 548.50M | 493.00M | 454.90M | 435.80M | 439.70M | 490.40M | 509.80M | 543.50M | 553.70M | 432.20M | 398.30M | 368.10M | 299.50M | 247.50M | 229.30M | 204.00M | 184.30M | 177.70M | 136.20M |
| EBITDA | 8.57B | 10.18B | 9.82B | 8.53B | 7.23B | 7.63B | 6.26B | 5.06B | 5.02B | 4.71B | 6.99B | 7.05B | 6.91B | 8.15B | 7.74B | 43.30M | 5.85B | 4.93B | 4.38B | 4.26B | 4.05B | 3.82B | 4.18B | 4.00B | 3.80B | 3.31B | 2.95B | 2.59B | 2.54B | 2.23B | 1.05B | 1.52B | 2.07B | 1.79B | 1.39B | 1.25B | 779.30M | 1.04B | 900.60M |
| EBITDA Ratio | 25.11% | 33.05% | 30.86% | 31.14% | 29.59% | 44.87% | 33.74% | 20.19% | 22.52% | 20.38% | 22.63% | 19.95% | 29.56% | 35.33% | 35.46% | 66.09% | 36.36% | 36.68% | 35.51% | 35.51% | 33.61% | 32.60% | 36.53% | 32.35% | 37.37% | 35.65% | 54.97% | 31.54% | 36.45% | 40.68% | 15.52% | 24.27% | 34.18% | 33.27% | 29.43% | 29.04% | 21.39% | 25.75% | 25.07% |
| Operating Income | 6.99B | 7.13B | 6.36B | 6.06B | 4.97B | 6.19B | 2.15B | 3.46B | 2.69B | 2.66B | 5.37B | 4.73B | 5.53B | 6.77B | 6.37B | 5.53B | 4.80B | 4.13B | 3.65B | 3.66B | 3.50B | 3.33B | 3.73B | 3.56B | 3.36B | 2.82B | 2.46B | 2.05B | 1.98B | 1.79B | 652.60M | 1.16B | 1.77B | 1.54B | 1.16B | 1.05B | 595.00M | 860.30M | 764.40M |
| Operating Income Ratio | 20.48% | 24.97% | 22.45% | 24.69% | 22.29% | 28.78% | 9.38% | 16.30% | 13.47% | 13.56% | 23.24% | 20.94% | 22.76% | 29.35% | 29.17% | 27.13% | 25.78% | 26.29% | 24.91% | 26.40% | 27.83% | 30.04% | 32.31% | 32.77% | 33.63% | 30.58% | 28.86% | 27.86% | 29.30% | 31.43% | 10.11% | 18.74% | 30.88% | 29.65% | 27.90% | 25.72% | 16.33% | 23.12% | 23.37% |
| Total Other Income/Expenses | -432.90M | -938.40M | -1.15B | 788.90M | -493.90M | -2.35B | -1.95B | -84.80M | -802.10M | -328.40M | 398.30M | 392.90M | -968.40M | -247.00M | -1.01B | -6.84B | -926.10M | -707.40M | -931.10M | -716.80M | -240.10M | 130.00M | -177.70M | 299.00M | -118.30M | -159.50M | 442.80M | 84.50M | -216.20M | -96.30M | 49.30M | 26.80M | 110.90M | 59.60M | 165.10M | 69.00M | 0.00 | 16.00M | 32.20M |
| Income Before Tax | 6.55B | 6.81B | 6.16B | 7.23B | 5.27B | 3.68B | 2.20B | 3.37B | 2.79B | 3.00B | 5.89B | 5.41B | 5.35B | 6.53B | 5.36B | -1.31B | 3.88B | 3.42B | 2.72B | 2.94B | 3.26B | 3.46B | 3.55B | 3.86B | 3.25B | 2.67B | 510.20M | 2.03B | 1.77B | 1.70B | 701.90M | 1.18B | 1.88B | 1.60B | 1.33B | 1.12B | 595.00M | 876.30M | 796.60M |
| Income Before Tax Ratio | 19.21% | 23.85% | 21.74% | 29.46% | 23.59% | 17.12% | 9.61% | 15.90% | 13.98% | 15.30% | 25.48% | 23.93% | 22.03% | 28.28% | 24.54% | -6.42% | 20.81% | 21.78% | 18.56% | 21.23% | 25.92% | 31.21% | 30.77% | 35.52% | 32.44% | 28.85% | 5.99% | 27.65% | 26.10% | 29.74% | 10.88% | 19.17% | 32.82% | 30.80% | 31.85% | 27.42% | 16.33% | 23.55% | 24.36% |
| Income Tax Expense | 1.31B | 561.60M | 573.80M | 1.04B | 628.00M | 529.50M | 2.40B | 636.40M | 381.60M | 609.80M | 1.20B | 1.32B | 1.00B | 1.46B | 1.03B | 764.30M | 923.80M | 755.30M | 715.90M | 1.13B | 700.90M | 749.80M | 742.70M | 800.90M | 698.70M | 568.70M | 895.30M | 507.80M | 459.00M | 513.50M | 210.80M | 354.70M | 564.50M | 471.70M | 390.40M | 354.80M | 184.50M | 318.10M | 279.00M |
| Net Income | 5.24B | 6.24B | 5.58B | 6.19B | 4.64B | 3.23B | -204.10M | 2.74B | 2.41B | 2.39B | 4.68B | 4.09B | 4.35B | 5.07B | 4.33B | -2.07B | 2.95B | 2.66B | 1.98B | 1.81B | 2.56B | 2.71B | 2.78B | 3.06B | 2.72B | 2.10B | -385.10M | 1.52B | 2.29B | 1.29B | 480.20M | 708.70M | 1.31B | 1.13B | 939.50M | 761.00M | 643.70M | 558.20M | 517.60M |
| Net Income Ratio | 15.36% | 21.88% | 19.71% | 25.24% | 20.78% | 15.04% | -0.89% | 12.90% | 12.07% | 12.19% | 20.27% | 18.09% | 17.90% | 21.97% | 19.82% | -10.17% | 15.85% | 16.97% | 13.52% | 13.06% | 20.35% | 24.45% | 24.08% | 28.15% | 27.20% | 22.71% | -4.52% | 20.74% | 33.87% | 22.52% | 7.44% | 11.49% | 22.96% | 21.71% | 22.50% | 18.70% | 17.67% | 15.00% | 15.83% |
| EPS | 5.80 | 6.93 | 6.15 | 6.82 | 4.98 | 3.14 | -0.19 | 2.59 | 2.27 | 2.23 | 4.33 | 3.67 | 3.90 | 4.58 | 3.94 | -1.89 | 2.71 | 2.45 | 1.82 | 1.67 | 2.38 | 2.51 | 2.58 | 2.83 | 2.50 | 1.91 | -0.35 | 1.39 | 2.02 | 1.11 | 0.40 | 0.61 | 1.13 | 0.98 | 0.80 | 0.67 | 0.56 | 0.51 | 0.47 |
| EPS Diluted | 5.80 | 6.90 | 6.12 | 6.79 | 4.96 | 3.13 | -0.19 | 2.58 | 2.26 | 2.23 | 4.32 | 3.66 | 3.90 | 4.58 | 3.94 | -1.89 | 2.71 | 2.45 | 1.81 | 1.66 | 2.37 | 2.50 | 2.55 | 2.79 | 2.46 | 1.87 | -0.34 | 1.36 | 2.02 | 1.11 | 0.40 | 0.61 | 1.13 | 0.98 | 0.80 | 0.67 | 0.56 | 0.51 | 0.47 |
| Weighted Avg Shares Out | 903.52M | 901.74M | 906.96M | 907.63M | 931.06M | 1.03B | 1.05B | 1.06B | 1.06B | 1.07B | 1.08B | 1.11B | 1.11B | 1.11B | 1.10B | 1.09B | 1.09B | 1.09B | 1.09B | 1.08B | 1.08B | 1.08B | 1.08B | 1.08B | 1.09B | 1.10B | 1.10B | 1.09B | 1.14B | 1.16B | 1.20B | 1.16B | 1.16B | 1.15B | 1.17B | 1.14B | 1.15B | 1.09B | 1.10B |
| Weighted Avg Shares Out (Dil) | 903.28M | 904.62M | 911.68M | 912.51M | 935.68M | 1.03B | 1.05B | 1.06B | 1.07B | 1.07B | 1.08B | 1.12B | 1.11B | 1.11B | 1.10B | 1.09B | 1.09B | 1.09B | 1.09B | 1.09B | 1.08B | 1.08B | 1.09B | 1.10B | 1.11B | 1.12B | 1.13B | 1.12B | 1.18B | 1.17B | 1.20B | 1.16B | 1.16B | 1.15B | 1.17B | 1.14B | 1.15B | 1.09B | 1.10B |
Source: https://incomestatements.info
Category: Stock Reports